Table 1

Baseline characteristics of patients with steroid-refractory ICI-pneumonitis by immunosuppressive treatment

Therapy type	Intravenous immunoglobulin	Infliximab	Combination
Therapy type	Intravenous immunoglobulin	Infliximab	Combination	Total patients, n (%)	7	2	3
Baseline characteristics
Age at ICI-pneumonitis diagnosis (mean, years)	66	66	68
Sex
Male	4 (57)	0 (0)	2 (67)
Female	3 (43)	2 (100)	1 (33)
Race
Caucasian	6 (86)	2 (100)	3 (100)
African-American	1 (14)	0 (0)	0 (0)
Smoking status
Never	3 (43)	0 (0)	0 (0)
Current/former	4 (57)	2 (100)	3 (100)
Pack year history (mean, years)	29.4	37.5	32.5
Tumor histology
Lung carcinoma	5 (71)	2 (100)	2 (67)
Non-small cell lung carcinoma	4 (80)	2 (100)	2 (100)
Small cell lung carcinoma	1 (20)	0 (0)	0 (0)
Oropharyngeal squamous cell carcinoma	0 (0)	0 (0)	1 (33)
Renal cell carcinoma	0 (0)	0 (0)	0 (0)
Pancreatic adenocarcinoma	0 (0)	0 (0)	0 (0)
Initial cancer stage*
II	1 (14)	1 (50)	1 (33)
III	3 (43)	0 (0)	0 (0)
IV	3 (43)	1 (50)	2 (67)
Anticancer therapy
Prior chemotherapy	6 (86)	2 (100)	3 (100)
Initial surgery	1 (14)	0 (0)	1 (33)
Prior chest radiation therapy†	4 (57)	1 (50)	2 (67)
PD-1/PD-L1 monotherapy	2 (29)	1 (50)	3 (100)
Durvalumab	2 (100)	0 (0)	1 (33)
Nivolumab	0 (0)	1 (100)	1 (33)
Pembrolizumab	0 (0)	0 (0)	1 (33)
PD-1/PD-L1-based combinations	5 (71)	1 (50)	0 (0)
Pembrolizumab+chemotherapy	4 (80)	0 (0)	0 (0)
Nivolumab+ipilimumab	1 (20)	1 (100)	0 (0)
ICI response at 3 months‡
Partial response	1 (14)	1 (50)	1 (33)
Stable disease	4 (57)	0 (0)	0 (0)
Progressive disease	2 (29)	1 (50)	2 (67)

*AJCC staging system.
†Dose of chest radiation in the range of 8–66 Gy given 276–739 days prior to steroid-refractory ICI-pneumonitis onset.
‡As defined by RECIST V.1.1 criteria.
ICI, immune-checkpoint inhibitor; PD, progressive disease.